MA30409B1 - Amino-pyrimidine 2,6-substituee-4-mono-substituee en tant qu'antagoniste du recepteur de la prostaglandine d2. - Google Patents
Amino-pyrimidine 2,6-substituee-4-mono-substituee en tant qu'antagoniste du recepteur de la prostaglandine d2.Info
- Publication number
- MA30409B1 MA30409B1 MA31375A MA31375A MA30409B1 MA 30409 B1 MA30409 B1 MA 30409B1 MA 31375 A MA31375 A MA 31375A MA 31375 A MA31375 A MA 31375A MA 30409 B1 MA30409 B1 MA 30409B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutically
- substituted
- urticaria
- hydrate
- inflammation
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000024780 Urticaria Diseases 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 230000002008 hemorrhagic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 238000006748 scratching Methods 0.000 abstract 1
- 230000002393 scratching effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) DANS LAQUELLE R1 ET R2 SONT TELS QUE DÉFINIS DANS LA PRÉSENTE OU UN SEL, HYDRATE OU SOLVATE ACCEPTABLE DU POINT DE VUE PHARMACEUTIQUE DE CELUI-CI, UN PROMÉDICAMENT ACCEPTABLE DU POINT DE VUE PHARMACEUTIQUE DE CELUI-CI OU UN SEL, HYDRATE OU SOLVATE ACCEPTABLE DU POINT DE VUE PHARMACEUTIQUE DU PROMÉDICAMENT, UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UNE QUANTITÉ EFFICACE DU POINT DE VUE PHARMACEUTIQUE D'UN OU PLUSIEURS COMPOSÉS DE L'INVENTION EN MÉLANGE AVEC UN VÉHICULE ACCEPTABLE DU POINT DE VUE PHARMACEUTIQUE, UN PROCÉDÉ DE TRAITEMENT D'UN PATIENT SOUFFRANT D'UN TROUBLE MÉDIÉ PAR LA PGD2 Y COMPRIS, MAIS SANS Y ÊTRE LIMITÉ, UNE MALADIE ALLERGIQUE (TELLE QUE LA RHINITE ALLERGIQUE, LA CONJONCTIVITE ALLERGIQUE, LA DERMATITE ATOPIQUE, L'ASTHME BRONCHIQUE ET UNE ALLERGIE ALIMENTAIRE), LA MASTOCYTOSE SYSTÉMIQUE, DES TROUBLES S'ACCOMPAGNANT D'UNE ACTIVATION SYSTÉMIQUE DES MASTOCYTES, LE CHOC ANAPHYLACTIQUE, LA BRONCHOCONSTRICTION, LA BRONCHITE, L'URTICAIRE, L'ECZÉMA, DES MALADIES S'ACCOMPAGNANT DE DÉMANGEAISONS (TELLES QUE LA DERMATITE ATOPIQUE ET L'URTICAIRE), DES MALADIES (TELLES QUE LA CATARACTE, LE DÉCOLLEMENT DE LA RÉTINE, UNE INFLAMMATION, UNE INFECTION ET DES TROUBLES DU SOMMEIL) LESQUELLES SONT GÉNÉRÉES DE FAÇON SECONDAIRE EN CONSÉQUENCE D'UN COMPORTEMENT ACCOMPAGNANT DES DÉMANGEAISONS (TEL QUE LE FAIT DE SE GRATTER OU DE SE FRAPPER), UNE INFLAMMATION, DES BRONCHOPNEUMOPATHIES OBSTRUCTIVES CHRONIQUES, UNE LÉSION D'ISCHÉMIE-REPERFUSION, UN ACCIDENT CÉRÉBROVASCULAIRE, LA POLYARTHRITE RHUMATOÏDE CHRONIQUE, LA PLEURÉSIE, LA RECTOCOLITE HÉMORRAGIQUE ET SIMILAIRES, EN ADMINISTRANT AUDIT PATIENT UNE QUANTITÉ EFFICACE DU POINT DE VUE PHARMACEUTIQUE D'UN COMPOSÉ DE L'INVENTION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74467606P | 2006-04-12 | 2006-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30409B1 true MA30409B1 (fr) | 2009-05-04 |
Family
ID=38294040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31375A MA30409B1 (fr) | 2006-04-12 | 2008-11-10 | Amino-pyrimidine 2,6-substituee-4-mono-substituee en tant qu'antagoniste du recepteur de la prostaglandine d2. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090036469A1 (fr) |
| EP (1) | EP2010503A1 (fr) |
| JP (1) | JP2009533473A (fr) |
| KR (1) | KR20080108287A (fr) |
| CN (1) | CN101421252B (fr) |
| AR (1) | AR060403A1 (fr) |
| AU (1) | AU2007238052B2 (fr) |
| BR (1) | BRPI0710710A2 (fr) |
| CA (1) | CA2649083C (fr) |
| CR (1) | CR10249A (fr) |
| DO (1) | DOP2007000068A (fr) |
| EC (1) | ECSP088813A (fr) |
| HN (1) | HN2008001530A (fr) |
| MA (1) | MA30409B1 (fr) |
| MX (1) | MX2008011369A (fr) |
| NO (1) | NO20084291L (fr) |
| NZ (1) | NZ571793A (fr) |
| PE (1) | PE20080186A1 (fr) |
| RU (1) | RU2431631C2 (fr) |
| TN (1) | TNSN08339A1 (fr) |
| TW (1) | TW200815395A (fr) |
| UA (1) | UA95950C2 (fr) |
| UY (1) | UY30283A1 (fr) |
| WO (1) | WO2007121280A1 (fr) |
| ZA (1) | ZA200807380B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5039594B2 (ja) * | 2008-02-08 | 2012-10-03 | 株式会社日立ハイテクノロジーズ | レビュー装置，検査領域設定支援システム、および、欠陥の画像得方法 |
| AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| CA2793223A1 (fr) * | 2010-03-16 | 2011-09-22 | Aventis Pharmaceuticals Inc. | Pyrimidines substituees en tant qu'antagonistes du recepteur d2 de prostaglandines |
| MX2012010038A (es) * | 2010-03-16 | 2012-10-01 | Aventis Pharma Inc | Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2. |
| CA2805452C (fr) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | Derives d'heterocyclyle substitues par un 1-phenyle et leur utilisation en tant que modulateurs des recepteurs de la prostaglandine d2 |
| EP2621276B1 (fr) * | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alcoxy pyrimidine inhibiteur de pde10 |
| TW201331179A (zh) | 2011-12-21 | 2013-08-01 | Actelion Pharmaceuticals Ltd | 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途 |
| EP2885307A1 (fr) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | Dérivés hétérocyclylés 1-phényl-substitués et leur utilisation en tant que modulateurs du récepteur de la prostaglandine d2 |
| EP2912458B1 (fr) | 2012-10-24 | 2018-07-18 | NYU Winthrop Hospital | Biomarqueurs non-invasifs pour identifier les sujets à risque d'accouchement prématuré |
| CA2930008A1 (fr) * | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Derive de carboxymethylpiperidine |
| MY195016A (en) | 2014-08-04 | 2023-01-03 | Nuevolution As | Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| AU2020347662B2 (en) * | 2019-09-13 | 2026-07-09 | Meiji Co., Ltd. | Solid food and solid milk |
| WO2021113710A1 (fr) | 2019-12-04 | 2021-06-10 | Progenity, Inc. | Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié |
| AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| BR112022012205A2 (pt) | 2019-12-20 | 2022-09-13 | Nuevolution As | Compostos ativos para receptores nucleares |
| JP7713954B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| CA3174252A1 (fr) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Composes actifs vis-a-vis des recepteurs nucleaires |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3644799A1 (de) * | 1986-06-04 | 1987-12-10 | Hoechst Ag | Neue pyrimidin-derivate, deren herstellung und verwendung |
| US5047554A (en) * | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
| SE0200411D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| GT200600457A (es) * | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
-
2007
- 2007-04-10 DO DO2007000068A patent/DOP2007000068A/es unknown
- 2007-04-10 AR ARP070101501A patent/AR060403A1/es not_active Application Discontinuation
- 2007-04-12 UA UAA200813109A patent/UA95950C2/ru unknown
- 2007-04-12 MX MX2008011369A patent/MX2008011369A/es active IP Right Grant
- 2007-04-12 NZ NZ571793A patent/NZ571793A/en not_active IP Right Cessation
- 2007-04-12 EP EP07760526A patent/EP2010503A1/fr not_active Withdrawn
- 2007-04-12 JP JP2009505615A patent/JP2009533473A/ja not_active Abandoned
- 2007-04-12 PE PE2007000450A patent/PE20080186A1/es not_active Application Discontinuation
- 2007-04-12 CN CN2007800127354A patent/CN101421252B/zh not_active Expired - Fee Related
- 2007-04-12 AU AU2007238052A patent/AU2007238052B2/en not_active Expired - Fee Related
- 2007-04-12 WO PCT/US2007/066481 patent/WO2007121280A1/fr not_active Ceased
- 2007-04-12 UY UY30283A patent/UY30283A1/es not_active Application Discontinuation
- 2007-04-12 TW TW096112790A patent/TW200815395A/zh unknown
- 2007-04-12 CA CA2649083A patent/CA2649083C/fr not_active Expired - Fee Related
- 2007-04-12 RU RU2008144578/04A patent/RU2431631C2/ru not_active IP Right Cessation
- 2007-04-12 KR KR1020087024764A patent/KR20080108287A/ko not_active Withdrawn
- 2007-04-12 BR BRPI0710710-2A patent/BRPI0710710A2/pt not_active IP Right Cessation
-
2008
- 2008-08-26 CR CR10249A patent/CR10249A/es not_active Application Discontinuation
- 2008-08-27 TN TNP2008000339A patent/TNSN08339A1/en unknown
- 2008-08-27 ZA ZA200807380A patent/ZA200807380B/xx unknown
- 2008-10-07 US US12/246,918 patent/US20090036469A1/en not_active Abandoned
- 2008-10-09 EC EC2008008813A patent/ECSP088813A/es unknown
- 2008-10-10 HN HN2008001530A patent/HN2008001530A/es unknown
- 2008-10-14 NO NO20084291A patent/NO20084291L/no not_active Application Discontinuation
- 2008-11-10 MA MA31375A patent/MA30409B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2649083C (fr) | 2011-06-28 |
| MX2008011369A (es) | 2008-09-18 |
| JP2009533473A (ja) | 2009-09-17 |
| HK1131975A1 (en) | 2010-02-12 |
| WO2007121280A1 (fr) | 2007-10-25 |
| UA95950C2 (en) | 2011-09-26 |
| AU2007238052A1 (en) | 2007-10-25 |
| RU2431631C2 (ru) | 2011-10-20 |
| BRPI0710710A2 (pt) | 2011-08-16 |
| KR20080108287A (ko) | 2008-12-12 |
| AU2007238052B2 (en) | 2011-12-22 |
| NZ571793A (en) | 2011-08-26 |
| AR060403A1 (es) | 2008-06-11 |
| UY30283A1 (es) | 2007-11-30 |
| CN101421252B (zh) | 2011-10-12 |
| TW200815395A (en) | 2008-04-01 |
| HN2008001530A (es) | 2012-01-17 |
| CN101421252A (zh) | 2009-04-29 |
| PE20080186A1 (es) | 2008-04-15 |
| ECSP088813A (es) | 2008-11-27 |
| NO20084291L (no) | 2008-11-11 |
| EP2010503A1 (fr) | 2009-01-07 |
| CR10249A (es) | 2008-11-26 |
| CA2649083A1 (fr) | 2007-10-25 |
| RU2008144578A (ru) | 2010-05-20 |
| US20090036469A1 (en) | 2009-02-05 |
| TNSN08339A1 (en) | 2009-12-29 |
| DOP2007000068A (es) | 2007-10-31 |
| ZA200807380B (en) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29259B1 (fr) | 2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2 | |
| MA30643B1 (fr) | 2-phenylindoles en tant qu'antagonistes du recepteur de la prostaglandine d2. | |
| MA30005B1 (fr) | Sel dihydrogenophosphate d'un antagoniste du recepteur de la prostaglandine d2 | |
| EP2344475B1 (fr) | Quinazolinone, quinolone et analogues apparentés en tant que modulateurs de sirtuine | |
| EP2912019B1 (fr) | Inhibiteurs hétéroaryle de pde4 | |
| TNSN07098A1 (en) | 2,6- substituted -4- monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
| MX2008011369A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2. | |
| US20060229265A1 (en) | Nicotinamide riboside and analogues thereof | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| WO2006094235A1 (fr) | Composés hétérocycliques liquéfiés et leur utilisation comme modulateurs de sirtuine | |
| MA30412B1 (fr) | Composés Pharmaceutiques | |
| MA27847A1 (fr) | Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle. | |
| JP2009503113A (ja) | サーチュイン調節因子としてのイミダゾピリジン誘導体 | |
| MA31326B1 (fr) | Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds | |
| SG172154A1 (en) | Phthalazinone and related analogs as sirtuin modulators | |
| US20130045975A1 (en) | Bicyclic heteroaryl inhibitors of pde4 | |
| EP1486491A4 (fr) | Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif | |
| US20190048016A1 (en) | Substituted bridged urea analogs as sirtuin modulators | |
| GEAP202516743A (en) | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 | |
| Balzano et al. | Leukotriene receptor antagonists in the treatment of asthma: an update | |
| JP2003535821A (ja) | 緑内障を治療するための５−ヒドロキシインダゾール誘導体 | |
| JP2016528227A (ja) | ウレア化合物および酵素阻害剤としてのそれらの使用 | |
| CN105793247A (zh) | 咪唑甲酰胺类及其作为faah抑制剂的用途 | |
| PT91613B (pt) | Processo para a preparacao de derivados anti-hipertensivos de 3-piperidinil- -indazole | |
| RU2613973C1 (ru) | Новый эффективный ингибитор киназы 4, ассоциированной с интерлейкином-1 (irak4) |